诺思格收盘上涨1.94%，滚动市盈率37.20倍，总市值56.32亿元

Core Insights - The closing price of Norscare on December 12 was 58.31 yuan, reflecting an increase of 1.94%, with a rolling PE ratio of 37.20 times and a total market capitalization of 5.632 billion yuan [1] - In comparison to the medical services industry, which has an average PE ratio of 49.50 times and a median of 61.79 times, Norscare ranks 25th [1] - On December 12, the net inflow of main funds into Norscare was 8.999 million yuan, with a total inflow of 35.8925 million yuan over the past five days [1] - Norscare's main business is providing comprehensive drug clinical research and development services to global pharmaceutical companies and research institutions, with its primary product being drug clinical trials [1] - For the third quarter of 2025, Norscare reported revenue of 607 million yuan, an increase of 8.09% year-on-year, and a net profit of 95.5668 million yuan, up 13.21% year-on-year, with a gross profit margin of 35.61% [1] Industry Comparison - Norscare's PE (TTM) is 37.20, while the industry average is 49.50 and the industry median is 61.79 [2] - The total market capitalization of Norscare is 5.632 billion yuan, compared to the industry average market capitalization of 18.939 billion yuan and the industry median of 7.390 billion yuan [2] - Other companies in the industry have varying PE ratios, with WuXi AppTec at 18.72 and a market cap of 280.622 billion yuan, and other notable companies like Mindray and Aier Eye Hospital showing higher PE ratios [2]